0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > B7-H4

B7-H4

Brief Information

Name:V-set domain-containing T-cell activation inhibitor 1
Target Synonym:V-Set Domain-Containing T-Cell Activation Inhibitor 1,Immune costimulatory protein B7-H4,B7h.5,B7 homolog 4,T-cell costimulatory molecule B7x,V-Set Domain Containing T Cell Activation Inhibitor 1,B7X,B7 Family Member, H4,T Cell Costimulatory Molecule B7x,
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Part of Bioactivity data

B74-H82E2-ELISA
Biotinylated Human B7-H4, Avitag,His Tag (recommended for biopanning)Biotinylated Human B7-H4, Avitag,His Tag (recommended for biopanning) (Cat. No. B74-H82E2) ELISA bioactivity

Immobilized Anti-Human B7-H4 MAb, Human IgG1 at 2 μg/mL (100 μL/well) can bind Biotinylated Human B7-H4, Avitag,His Tag (recommended for biopanning) (Cat. No. B74-H82E2) with a linear range of 3-48 ng/mL (QC tested).

B74-H5256-ELISA
Human B7-H4, Fc Tag, low endotoxinHuman B7-H4, Fc Tag, low endotoxin (Cat. No. B74-H5256) ELISA bioactivity

Immobilized Human B7-H4, Fc Tag, low endotoxin (Cat. No. B74-H5256) at 0.5 μg/mL (100 μL/well) can bind Anti-B7-H4 MAb (Human IgG1) with a linear range of 0.2-8 ng/mL (QC tested).

Customer Reviews

Synonym Name

B7-H4,VTCN1,B7S1,B7h.5

Background

V-set domain-containing T-cell activation inhibitor 1 (VTCN1) is also known as Immune costimulatory protein B7-H4, Protein B7S1, T-cell costimulatory molecule B7x, B7H4, which belongs to the immunoglobulin superfamily and BTN/MOG family. VTCN1 contains two Ig-like V-type (immunoglobulin-like) domains. The expression of VTCN1 is up-regulated by IL6 and IL10 and is inhibited by GM-CSF and IL4 on antigen-presenting cells (APCs). VTCN1 / B7-H4 negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. VTCN1 involved in promoting epithelial cell transformation.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
FPA-150 FPA-150 Phase 1 Clinical Five Prime Therapeutics Ovarian Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Breast Neoplasms; Endometrial Neoplasms Details
NC-762 NC-762 Phase 2 Clinical Ovarian Neoplasms; Solid tumours; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop